Phase 3
Completed N=1,164
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Source: ClinicalTrials.gov NCT01196091 ↗Enrolled (actual)
1,164
Serious AEs
13.4%
Results posted
Jun 2018
Primary outcomePrimary: Percentage of Participants Achieving an SLE Responder Index Response at Week 52 — 31.8; 35.2; 29.3 percentage of participants
◆ Published Evidence
Established
74citations · ~8 / year
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
Summary
The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in participants with active SLE.
Linked Publications (5)
-
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
-
Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression.
-
A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus.
-
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
-
B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Achieving an SLE Responder Index Response at Week 52 |
31.8; 35.2; 29.3 | — |
| SECONDARY Percentage Participants Able to Decrease Dose of Prednisone or Equivalent With No Increase in Disease Activity at Week 52 |
15.5; 17.0; 16.4 | — |
| SECONDARY Change From Baseline to 52 Weeks in Anti-double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Level |
107.2; 110.4; 107.1 | — |
| SECONDARY Change From Baseline to 52 Week Endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) Score |
-4.7; -4.9; -4.6 | — |
| SECONDARY Time to First Severe SLE Flare (SFI) |
— | — |
| SECONDARY Percentage of Participants With No Worsening in Physician Global Assessment (PGA) Score at 52 Weeks |
64.3; 61.4; 58.0 | — |
| SECONDARY Change From Baseline to 52 Week Endpoint in Brief Fatigue Inventory (BFI) Scores |
-0.9; -0.9; -0.6 | — |
| SECONDARY Change From Baseline to 52 Week Endpoint Lupus Quality of Life (LupusQoL) Domain Scores |
73.7; 72.8; 72.8; 75.2; 72.4; 73.1 | — |
| SECONDARY Time to First New British Isles Lupus Assessment Group (BILAG A) or 2 New BILAG B SLE Flares |
— | — |
| SECONDARY Change From Baseline to 52 Week Endpoint in PGA |
-20.8; -20.8; -20.2 | — |
| SECONDARY Percentage of Participants With an Increase in Corticosteroids Dose at 52 Weeks |
6.7; 9.1; 8.8 | — |
| SECONDARY Change From Baseline to 52 Weeks Endpoint in SELENA-SLEDAI Disease Activity Score |
-4.6; -4.7; -4.8 | — |
| SECONDARY Percentage of Participants Achieving a Response as Measured by Modified SRI With No BILAG A or No More Than 1 BILAG B Organ Domain Flares at 52 Weeks |
31.8; 35.2; 29.6; 68.2; 64.8; 70.4 | — |
| SECONDARY Number of Participants With No New BILAG A and No More Than One New BILAG B Disease Activity Scores Compared to Baseline |
247; 234; 219 | — |
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria
- Have positive antinuclear antibodies (ANA)
- Agree not to become pregnant throughout the course of the trial
- Have a screening SELENA-SLEDAI score ≥6. (The participant must be actively exhibiting all the symptoms scored on the screening SELENA-SLEDAI on the day of screening.)
Exclusion Criteria
- Have active severe Lupus kidney disease
- Have active Central Nervous System or peripheral neurologic disease
- Have received intravenous immunoglobulin (IVIg) within 180 days of randomization
- Have active or recent infection within 30 days of screening
- Have had a serious infection within 90 days of randomization
- Have evidence or test positive for Hepatitis B
- Have Hepatitis C
- Are human immunodeficiency virus (HIV) positive
- Have evidence of active or latent tuberculosis (TB)
- Presence of significant laboratory abnormalities at screening
- Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or basal cell or squamous epithelial skin cell that were completely resected with no reoccurrence in the 3 yrs prior to randomization
- Have received greater than 40 mgs of prednisone or equivalent in the past 30 days
- Have changed your dose of antimalarial drug in the past 30 days
- Have changed your dose of immunosuppressive drug in the past 90 days
- Have previously received rituximab
Data sourced from ClinicalTrials.gov (NCT01196091) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.